tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Judah Frommer, 178 are a BUY (68.99%), 75 are a HOLD (29.07%), 5 are a SELL (1.94%).
Analyst Judah Frommer, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 68.37% that have a potential upside of 36.31% achieved within 277 days.
Judah Frommer’s has documented 507 price targets and ratings displayed on 51 stocks. The coverage is on Consumer Defensive, Consumer Cyclical, Healthcare sectors.
Most recent stock forecast was given on INCY, yte at 20-Oct-2026.
Analyst best performing recommendations are on PROK (PROKIDNEY CORP.).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 5/15/2023. The price target of $151 was fulfilled within 1 day with a profit of $6.19 (3.94%) receiving and performance score of 39.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-Nov-2026
$140
$8.86 (6.76%)
$140
Hold Since 02-Apr-2024
$135
$3.86 (2.94%)
$142
1 months 10 days ago
(29-Sep-2026)
21/23 (91.3%)
$21.7 (19.15%)
143
Buy Since 17-Oct-2025
$160
$28.86 (22.01%)
$131
2 months 4 days ago
(04-Sep-2026)
8/10 (80%)
$28.58 (21.75%)
67
Hold Since 05-Sep-2024
$121
$-10.14 (-7.73%)
$101
2 months 8 days ago
(31-Aug-2026)
36/43 (83.72%)
$-5.59 (-4.42%)
222
Hold Since 15-Nov-2021
$145
$13.86 (10.57%)
$130
2 months 11 days ago
(28-Aug-2026)
17/17 (100%)
$16.74 (13.05%)
133
Which stock is Judah Frommer most bullish on?
Which stock is Judah Frommer most reserved on?
What Year was the first public recommendation made by Judah Frommer?
